Why the study?
Does epsilonaminocaproic acid increase the incidence of deep-vein thrombosis in patients undergoing retropubic prostatectomy?
Does epsilonaminocaproic acid increase the incidence of deep-vein thrombosis in patients undergoing retropubic prostatectomy?
Perioperative administration of epsilonaminocaproic acid does not increase the incidence of deep-vein thrombosis in patients undergoing retropubic prostatectomy.
Answers are grounded in this paper and cite their sources.
EACA may be used perioperatively in prostatectomy without DVT concern; confirms antifibrinolytic safety in this RCT.
Sixty-two patients undergoing retropubic prostatectomy were examined for evidence of deep-vein thrombosis using the 125I-fibrinogen technique. Patients were allocated randomly into two groups. The first grops was given the fibrinolytic inhibitor epsilonminocaproic acid (EACA) during the perioperative period, while the second group of patients acted as a control. The administration of EACA did not increase the incidence of deep-vein thrombosis after prostatectomy. This finding is discussed together with the possible role of the fibrinolytic system i postoperative venous thrombo-embolic disease.
No takes yet. Share an insight, caveat, or question.
Gordon-Smith et al. (1972) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: